Q-omics provides the consensus-scored GSAP profile across patient tissues and cancer cell-line models. GSAP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GSAP is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, GSAP RNA expression shows 19,515 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LUAD, and UVM as cancer lineages where GSAP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GSAP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GSAP survival associations across molecular data types. GSAP RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GSAP RNA expression–survival associations across cancer types. High GSAP expression shows unfavorable associations in LGG, but favorable associations in HNSC, BRCA, MESO, BLCA and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for GSAP RNA expression.
This table summarizes GSAP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GSAP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GSAP shows lower tumor expression in LUAD, THCA and LUSC and higher tumor expression in KIRC, COAD and HNSC. The LUAD box plot shows higher GSAP RNA expression in normal versus tumor tissue (log2 FC = −1.373, t-test p < 0.001).
This table shows molecular features associated with GSAP in patient tissues and cancer cell lines. In patient samples, GSAP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GSAP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
